Efficacy and safety of Cadonilimab in the treatment of recurrent/metastatic and advanced cervical cancer: a systematic review and meta-analysis.

ABSTRACT:

Objective

To investigate the efficacy and safety of Cadonilimab in patients with metastatic, recurrent, and advanced cervical cancer.

Methods

Computerized searches were performed in PubMed, Embase, Cochrane Library, Wiley Online Library, Web of Science, and the CBM database from their inception until October 4, 2025, to collect published studies on Cadonilimab for cervical cancer. A single-arm rate meta-analysis was conducted using R software (version 4.4.1) to evaluate outcome measures including efficacy, safety, and prognostic indicators.

Results

Ten studies involving 728 patients were included. The meta-analysis yielded the following pooled results: the overall response rate (ORR) was 57.8% (95% CI = 44.5%-70.2%), the disease control rate (DCR) was 81.8% (95% CI =

SUBMITTER: Zhuang Q 

PROVIDER: S-EPMC12832733 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature